Recent News

• 05.14.2025 - Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal
• 05.13.2025 - Daxor’s Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems
• 05.07.2025 - Florida Healthcare Leader Embraces DAXOR Blood Volume Analysis Technology
• 05.06.2025 - Three New Medical Centers Adopt Daxor’s Blood Volume Diagnostic Signaling Growing Clinical Acceptance
• 04.22.2025 - Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions
• 04.17.2025 - Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025
• 04.15.2025 - New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival
• 04.10.2025 - Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer
• 04.02.2025 - Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology’s 74th Annual Scientific Session and Expo
• 03.28.2025 - Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks

Recent Filings

• 04.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.20.2025 - 4/A Statement of changes in beneficial ownership of securities
• 03.14.2025 - N-CEN Annual Report for Registered Investment Companies
• 03.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2025 - 4 Statement of changes in beneficial ownership of securities